Hypersensitivity pneumonitis (HP) is a complex and heterogeneous interstitial lung disease (ILD) that occurs when susceptible individuals develop an exaggerated immune response to an inhaled antigen. In this review, we discuss the latest guidelines for the diagnostic evaluation of patients with suspected HP, the importance of identifying patients with fibrotic and progressive disease, and the evidence supporting the drugs commonly used in the treatment of HP. Differential diagnosis of HP can be challenging and requires a thorough exposure history, multidisciplinary discussion of clinical and radiologic data, and, in some cases, assessment of bronchoalveolar lavage lymphocytosis and histopathologic findings. Patients with HP may be categorised as having non-fibrotic or fibrotic HP. The presence of fibrosis is associated with worse outcomes. A proportion of patients with fibrotic HP develop a progressive phenotype, characterised by worsening fibrosis, decline in lung function and early mortality. There are no established guidelines for the treatment of HP. Antigen avoidance should be implemented wherever possible. Immunosuppressants are commonly used in patients with HP but have not been shown to slow the worsening of fibrotic disease. Nintedanib, a tyrosine kinase inhibitor, has been approved by the US Food and Drug Administration for slowing the progression of chronic fibrosing ILDs with a progressive phenotype, including progressive fibrotic HP. Non-pharmacological interventions, such as oxygen therapy, pulmonary rehabilitation and supportive care, may be important components of the overall care of patients with progressive HP.

Department of Biomedical Imaging and Image Guided Therapy Medical University of Vienna Vienna Austria

Department of Pulmonary and Critical Care Medicine University of Kansas Medical Center Kansas City KS USA

Department of Respiratory Medicine University Thomayer Hospital Prague Czech Republic

Zobrazit více v PubMed

Raghu G, Remy-Jardin M, Ryerson CJ, et al. . Diagnosis of hypersensitivity pneumonitis in adults. An official ATS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2020; 202: e36–e69. doi:10.1164/rccm.202005-2032ST PubMed DOI PMC

Fernández Pérez ER, Travis WD, Lynch DA, et al. . Executive summary diagnosis and evaluation of hypersensitivity pneumonitis: CHEST guideline and expert panel report. Chest 2021; 160: 595–615. doi:10.1016/j.chest.2021.03.067 PubMed DOI

Selman M, Pardo A, King TE, Jr. Hypersensitivity pneumonitis: insights in diagnosis and pathobiology. Am J Respir Crit Care Med 2012; 186: 314–324. doi:10.1164/rccm.201203-0513CI PubMed DOI

Vašáková M, Selman M, Morell F, et al. . Hypersensitivity pneumonitis: current concepts of pathogenesis and potential targets for treatment. Am J Respir Crit Care Med 2019; 200: 301–308. doi:10.1164/rccm.201903-0541PP PubMed DOI

Camarena A, Juárez A, Mejía M, et al. . Major histocompatibility complex and tumor necrosis factor-alpha polymorphisms in pigeon breeder's disease. Am J Respir Crit Care Med 2001; 163: 1528–1533. doi:10.1164/ajrccm.163.7.2004023 PubMed DOI

Newton CA, Batra K, Torrealba J, et al. . Telomere-related lung fibrosis is diagnostically heterogeneous but uniformly progressive. Eur Respir J 2016; 48: 1710–1720. doi:10.1183/13993003.00308-2016 PubMed DOI PMC

Ley B, Newton CA, Arnould I, et al. . The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med 2017; 5: 639–647. doi:10.1016/S2213-2600(17)30216-3 PubMed DOI PMC

Ley B, Torgerson DG, Oldham JM, et al. . Rare protein-altering telomere-related gene variants in patients with chronic hypersensitivity pneumonitis. Am J Respir Crit Care Med 2019; 200: 1154–1163. doi:10.1164/rccm.201902-0360OC PubMed DOI PMC

Furusawa H, Cardwell JH, Okamoto T, et al. . Chronic hypersensitivity pneumonitis, an interstitial lung disease with distinct molecular signatures. Am J Respir Crit Care Med 2020; 202: 1430–1444. doi:10.1164/rccm.202001-0134OC PubMed DOI PMC

Lee CT, Adegunsoye A, Chung JH, et al. . Characteristics and prevalence of domestic and occupational inhalational exposures across interstitial lung diseases. Chest 2021; 160: 209–218. doi:10.1016/j.chest.2021.02.026 PubMed DOI PMC

Johannson KA, Barnes H, Bellanger AP, et al. . Exposure assessment tools for hypersensitivity pneumonitis. An official American Thoracic Society workshop report. Ann Am Thorac Soc 2020; 17: 1501–1509. doi:10.1513/AnnalsATS.202008-942ST PubMed DOI PMC

Cormier Y, Israël-Assayag E. The role of viruses in the pathogenesis of hypersensitivity pneumonitis. Curr Opin Pulm Med 2000; 6: 420–423. doi:10.1097/00063198-200009000-00006 PubMed DOI

McSharry C, Banham SW, Boyd G. Effect of cigarette smoking on the antibody response to inhaled antigens and the prevalence of extrinsic allergic alveolitis among pigeon breeders. Clin Allergy 1985; 15: 487–494. doi:10.1111/j.1365-2222.1985.tb02299.x PubMed DOI

Ohtsuka Y, Munakata M, Tanimura K, et al. . Smoking promotes insidious and chronic farmer's lung disease, and deteriorates the clinical outcome. Intern Med 1995; 34: 966–971. doi:10.2169/internalmedicine.34.966 PubMed DOI

Selman M, Pardo A. When things go wrong: exploring possible mechanisms driving the progressive fibrosis phenotype in interstitial lung diseases. Eur Respir J 2021; 58: 2004507. doi:10.1183/13993003.04507-2020 PubMed DOI

Richerson HB, Bernstein IL, Fink JN, et al. . Guidelines for the clinical evaluation of hypersensitivity pneumonitis. Report of the subcommittee on hypersensitivity pneumonitis. J Allergy Clin Immunol 1989; 84: 839–844. doi:10.1016/0091-6749(89)90349-7 PubMed DOI

Lacasse Y, Selman M, Costabel U, et al. . Classification of hypersensitivity pneumonitis: a hypothesis. Int Arch Allergy Immunol 2009; 149: 161–166. doi:10.1159/000189200 PubMed DOI

Vourlekis JS, Schwarz MI, Cherniack RM, et al. . The effect of pulmonary fibrosis on survival in patients with hypersensitivity pneumonitis. Am J Med 2004; 116: 662–668. doi:10.1016/j.amjmed.2003.12.030 PubMed DOI

Hanak V, Golbin JM, Hartman TE, et al. . High-resolution CT findings of parenchymal fibrosis correlate with prognosis in hypersensitivity pneumonitis. Chest 2008; 134: 133–138. doi:10.1378/chest.07-3005 PubMed DOI

Mooney JJ, Elicker BM, Urbania TH, et al. . Radiographic fibrosis score predicts survival in hypersensitivity pneumonitis. Chest 2013; 144: 586–592. doi:10.1378/chest.12-2623 PubMed DOI

Churg A, Bilawich A, Wright JL. Pathology of chronic hypersensitivity pneumonitis. What is it? What are the diagnostic criteria? Why do we care? Arch Pathol Lab Med 2018; 142: 109–119. doi:10.5858/arpa.2017-0173-RA PubMed DOI

Ojanguren I, Morell F, Ramón MA, et al. . Long-term outcomes in chronic hypersensitivity pneumonitis. Allergy 2019; 74: 944–952. doi:10.1111/all.13692 PubMed DOI

Morell F, Villar A, Montero MÁ, et al. . Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013; 1: 685–694. doi:10.1016/S2213-2600(13)70191-7 PubMed DOI

Barnes H, Morisset J, Molyneaux P, et al. . A systematically derived exposure assessment instrument for chronic hypersensitivity pneumonitis. Chest 2020; 157: 1506–1512. doi:10.1016/j.chest.2019.12.018 PubMed DOI PMC

Fernández Pérez ER, Swigris JJ, Forssén AV, et al. . Identifying an inciting antigen is associated with improved survival in patients with chronic hypersensitivity pneumonitis. Chest 2013; 144: 1644–1651. doi:10.1378/chest.12-2685 PubMed DOI PMC

De Sadeleer LJ, Hermans F, De Dycker E, et al. . Effects of corticosteroid treatment and antigen avoidance in a large hypersensitivity pneumonitis cohort: a single-centre cohort study. J Clin Med 2018; 8: 14. doi:10.3390/jcm8010014 PubMed DOI PMC

Morell F, Ojanguren I, Cruz MJ. Diagnosis of occupational hypersensitivity pneumonitis. Curr Opin Allergy Clin Immunol 2019; 19: 105–110. doi:10.1097/ACI.0000000000000511 PubMed DOI

Ravaglia C, Bonifazi M, Wells AU, et al. . Safety and diagnostic yield of transbronchial lung cryobiopsy in diffuse parenchymal lung diseases: a comparative study versus video-assisted thoracoscopic lung biopsy and a systematic review of the literature. Respiration 2016; 91: 215–227. doi:10.1159/000444089 PubMed DOI

Cardasis JJ, MacMahon H, Husain AN. The spectrum of lung disease due to chronic occult aspiration. Ann Am Thorac Soc 2014; 11: 865–873. doi:10.1513/AnnalsATS.201310-360OC PubMed DOI

Adegunsoye A, Oldham JM, Chung JH, et al. . Phenotypic clusters predict outcomes in a longitudinal interstitial lung disease cohort. Chest 2018; 153: 349–360. doi:10.1016/j.chest.2017.09.026 PubMed DOI PMC

Fernández Pérez ER, Kong AM, Raimundo K, et al. . Epidemiology of hypersensitivity pneumonitis among an insured population in the United States: a claims-based cohort analysis. Ann Am Thorac Soc 2018; 15: 460–469. doi:10.1513/AnnalsATS.201704-288OC PubMed DOI

Salisbury ML, Gu T, Murray S, et al. . Hypersensitivity pneumonitis: radiologic phenotypes are associated with distinct survival time and pulmonary function trajectory. Chest 2019; 155: 699–711. doi:10.1016/j.chest.2018.08.1076 PubMed DOI PMC

Alberti ML, Malet Ruiz JM, Fernández ME, et al. . Comparative survival analysis between idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. Pulmonology 2020; 26: 3–9. doi:10.1016/j.pulmoe.2019.08.007 PubMed DOI

Brown KK, Martinez FJ, Walsh SLF, et al. . The natural history of progressive fibrosing interstitial lung diseases. Eur Respir J 2020; 55: 2000085. doi:10.1183/13993003.00085-2020 PubMed DOI PMC

Moua T, Westerly BD, Dulohery MM, et al. . Patients with fibrotic interstitial lung disease hospitalized for acute respiratory worsening: a large cohort analysis. Chest 2016; 149: 1205–1214. doi:10.1016/j.chest.2015.12.026 PubMed DOI

Choe J, Chae EJ, Kim YJ, et al. . Serial changes of CT findings in patients with chronic hypersensitivity pneumonitis: imaging trajectories and predictors of fibrotic progression and acute exacerbation. Eur Radiol 2021; 31: 3993–4003. doi:10.1007/s00330-020-07469-2 PubMed DOI

Suzuki A, Kondoh Y, Brown KK, et al. . Acute exacerbations of fibrotic interstitial lung diseases. Respirology 2020; 25: 525–534. doi:10.1111/resp.13682 PubMed DOI

Lima MS, Coletta EN, Ferreira RG, et al. . Subacute and chronic hypersensitivity pneumonitis: histopathological patterns and survival. Respir Med 2009; 103: 508–515. doi:10.1016/j.rmed.2008.12.016 PubMed DOI

Fernández Pérez ER, Sprunger DB, Ratanawatkul P, et al. . Increasing hypersensitivity pneumonitis-related mortality in the United States from 1988 to 2016. Am J Respir Crit Care Med 2019; 199: 1284–1287. doi:10.1164/rccm.201807-1258LE PubMed DOI

De Sadeleer LJ, Hermans F, De Dycker E, et al. . Impact of BAL lymphocytosis and presence of honeycombing on corticosteroid treatment effect in fibrotic hypersensitivity pneumonitis: a retrospective cohort study. Eur Respir J 2020; 55: 1901983. doi:10.1183/13993003.01983-2019 PubMed DOI

Wang P, Jones KD, Urisman A, et al. . Pathologic findings and prognosis in a large prospective cohort of chronic hypersensitivity pneumonitis. Chest 2017; 152: 502–509. doi:10.1016/j.chest.2017.02.011 PubMed DOI

Walsh SL, Sverzellati N, Devaraj A, et al. . Chronic hypersensitivity pneumonitis: high resolution computed tomography patterns and pulmonary function indices as prognostic determinants. Eur Radiol 2012; 22: 1672–1679. doi:10.1007/s00330-012-2427-0 PubMed DOI

Jacob J, Bartholmai BJ, Rajagopalan S, et al. . Automated computer-based CT stratification as a predictor of outcome in hypersensitivity pneumonitis. Eur Radiol 2017; 27: 3635–3646. doi:10.1007/s00330-016-4697-4 PubMed DOI

Adegunsoye A, Oldham JM, Bellam SK, et al. . Computed tomography honeycombing identifies a progressive fibrotic phenotype with increased mortality across diverse interstitial lung diseases. Ann Am Thorac Soc 2019; 16: 580–588. doi:10.1513/AnnalsATS.201807-443OC PubMed DOI PMC

Chung JH, Zhan X, Cao M, et al. . Presence of air trapping and mosaic attenuation on chest computed tomography predicts survival in chronic hypersensitivity pneumonitis. Ann Am Thorac Soc 2017; 14: 1533–1538. doi:10.1513/AnnalsATS.201701-035OC PubMed DOI

Gimenez A, Storrer K, Kuranishi L, et al. . Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. Thorax 2018; 73: 391–392. doi:10.1136/thoraxjnl-2017-210035 PubMed DOI

Solomon JJ, Chung JH, Cosgrove GP, et al. . Predictors of mortality in rheumatoid arthritis-associated interstitial lung disease. Eur Respir J 2016; 47: 588–596. doi:10.1183/13993003.00357-2015 PubMed DOI

Goh NS, Hoyles RK, Denton CP, et al. . Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis. Arthritis Rheumatol 2017; 69: 1670–1678. doi:10.1002/art.40130 PubMed DOI

Doubková M, Švancara J, Svoboda M, et al. . EMPIRE Registry, Czech part: impact of demographics, pulmonary function and HRCT on survival and clinical course in idiopathic pulmonary fibrosis. Clin Respir J 2018; 12: 1526–1535. doi:10.1111/crj.12700 PubMed DOI

Faverio P, Piluso M, De Giacomi F, et al. . Progressive fibrosing interstitial lung diseases: prevalence and characterization in two Italian referral centers. Respiration 2020; 99: 838–845. doi:10.1159/000509556 PubMed DOI

Mönkäre S, Haahtela T. Farmer's lung: a 5-year follow-up of eighty-six patients. Clin Allergy 1987; 17: 143–151. doi:10.1111/j.1365-2222.1987.tb02332.x PubMed DOI

Kokkarinen JI, Tukiainen HO, Terho EO. Effect of corticosteroid treatment on the recovery of pulmonary function in farmer's lung. Am Rev Respir Dis 1992; 145: 3–5. doi:10.1164/ajrccm/145.1.3 PubMed DOI

Wijsenbeek M, Kreuter M, Olson A, et al. . Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin 2019; 35: 2015–2024. doi:10.1080/03007995.2019.1647040 PubMed DOI

Idiopathic Pulmonary Fibrosis Clinical Research Network , Raghu G, Anstrom KJ, et al. . Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012; 366: 1968–1977. doi:10.1056/NEJMoa1113354 PubMed DOI PMC

Morisset J, Johannson KA, Vittinghoff E, et al. . Use of mycophenolate mofetil or azathioprine for the management of chronic hypersensitivity pneumonitis. Chest 2017; 151: 619–625. doi:10.1016/j.chest.2016.10.029 PubMed DOI PMC

Fiddler CA, Simler N, Thillai M, et al. . Use of mycophenolate mofetil and azathioprine for the treatment of chronic hypersensitivity pneumonitis – a single-centre experience. Clin Respir J 2019; 13: 791–794. doi:10.1111/crj.13086 PubMed DOI

Terras Alexandre A, Martins N, Raimundo S, et al. . Impact of azathioprine use in chronic hypersensitivity pneumonitis patients. Pulm Pharmacol Ther 2020; 60: 101878. doi:10.1016/j.pupt.2019.101878 PubMed DOI

Adegunsoye A, Oldham JM, Fernández Pérez ER, et al. . Outcomes of immunosuppressive therapy in chronic hypersensitivity pneumonitis. ERJ Open Res 2017; 3: 00016-2017. doi:10.1183/23120541.00016-2017 PubMed DOI PMC

Ferreira M, Borie R, Crestani B, et al. . Efficacy and safety of rituximab in patients with chronic hypersensitivity pneumonitis (cHP): a retrospective, multicentric, observational study. Respir Med 2020; 172: 106146. doi:10.1016/j.rmed.2020.106146 PubMed DOI

Wells AU, Brown KK, Flaherty KR, et al. . What's in a name? That which we call IPF, by any other name would act the same. Eur Respir J 2018; 51: 1800692. doi:10.1183/13993003.00692-2018 PubMed DOI

Wollin L, Distler JHW, Redente EF, et al. . Potential of nintedanib in treatment of progressive fibrosing interstitial lung diseases. Eur Respir J 2019; 54: 1900161. doi:10.1183/13993003.00161-2019 PubMed DOI PMC

Flaherty KR, Wells AU, Cottin V, et al. . Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med 2019; 381: 1718–1727. doi:10.1056/NEJMoa1908681 PubMed DOI

Cottin V, Richeldi L, Rosas I, et al. . Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. Respir Res 2021; 22: 84. doi:10.1186/s12931-021-01668-1 PubMed DOI PMC

Flaherty KR, Wells AU, Cottin V, et al. . Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. Eur Respir J 2021; in press [10.1183/13993003.04538-2020]. PubMed DOI PMC

Wells AU, Flaherty KR, Brown KK, et al. . Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med 2020; 8: 453–460. doi:10.1016/S2213-2600(20)30036-9 PubMed DOI

Shibata S, Furusawa H, Inase N. Pirfenidone in chronic hypersensitivity pneumonitis: a real-life experience. Sarcoidosis Vasc Diffuse Lung Dis 2018; 35: 139–142. doi:10.36141/svdld.v35i2.6170 PubMed DOI PMC

Mateos-Toledo H, Mejía-Ávila M, Rodríguez-Barreto Ó, et al. . An open-label study with pirfenidone on chronic hypersensitivity pneumonitis. Arch Bronconeumol 2020; 56: 163–169. doi:10.1016/j.arbr.2019.08.008 PubMed DOI

Behr J, Prasse A, Kreuter M, et al. . Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med 2021; 9: 476–486. doi:10.1016/S2213-2600(20)30554-3 PubMed DOI

Jacobs SS, Krishnan JA, Lederer DJ, et al. . Home oxygen therapy for adults with chronic lung disease. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med 2020; 202: e121–e141. doi:10.1164/rccm.202009-3608ST PubMed DOI PMC

Holland AE, Dowman LM, Hill CJ. Principles of rehabilitation and reactivation: interstitial lung disease, sarcoidosis and rheumatoid disease with respiratory involvement. Respiration 2015; 89: 89–99. doi:10.1159/000370126 PubMed DOI

Wijsenbeek MS, Holland AE, Swigris JJ, et al. . Comprehensive supportive care for patients with fibrosing interstitial lung disease. Am J Respir Crit Care Med 2019; 200: 152–159. doi:10.1164/rccm.201903-0614PP PubMed DOI

Fisher JH, Kolb M, Algamdi M, et al. . Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis. BMC Pulm Med 2019; 19: 223. doi:10.1186/s12890-019-0986-4 PubMed DOI PMC

Kern RM, Singer JP, Koth L, et al. . Lung transplantation for hypersensitivity pneumonitis. Chest 2015; 147: 1558–1565. doi:10.1378/chest.14-1543 PubMed DOI PMC

Leard LE, Holm AM, Valapour M, et al. . A consensus document for the selection of lung transplant candidates: an update from the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2021; 40: 1349–1379. doi:10.1016/j.healun.2021.07.005 PubMed DOI PMC

Histopathological aspects of usual interstitial pneumonia in patients with systemic connective tissue diseases